布地奈德联合复方异丙托溴铵雾化吸入治疗小儿急性喘息性支气管炎
DOI:
作者:
作者单位:

作者简介:

通讯作者:

基金项目:


Curative effect analysis of nebulized budesonide combined with ipratropium bromide on treating acute asthmatic bronchitis in children
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
    摘要:

    【摘要】目的 评价布地奈德混悬液联合复方异丙托溴铵溶液雾化吸入治疗小儿急性喘息性支气管炎的临床疗效。方法 随机将2016年6~12月就诊的120例急性喘息性支气管炎患儿按就诊顺序分为实验组和对照组,各60例, 两组除同时采用口服抗感染、止咳平喘药物治疗外, 实验组采用布地奈德混悬液联合复方异丙托溴铵溶液雾化吸入;对照组采用地塞米松注射液联合利巴韦林注射液、糜蛋白酶雾化吸入, 5天后比较两组临床疗效。结果 实验组治疗后喘息症状改善情况显著优于对照组, 差异有统计学意义(P<0.05);患儿在雾化吸入后均无明显不良反应。结论 布地奈德混悬液联合复方异丙托溴铵溶液雾化吸入治疗小儿急性喘息性支气管炎可缓解患儿喘息症状, 疗效显著、安全,具有临床价值。

    Abstract:

    【Abstract】Objective To evaluate the analysis of budesonide suspension for inhalation (pulmicort) combined with inhalation of the clinical curative effect of compound ipratropium bromide in the treatment of acute asthmatic bronchitis. Methods 120 patients with acute asthmatic bronchitis were randomly divided into experimental group and control group with 60 cases in each group. The experimental group with budesonide (pulmicort) combined with inhalation of ipratropium bromide solution for inhalation inhalation. The control group was treated with dexamethasone combined with leigh bhave lin and chymotrypsin inhalation therapy. The clinical efficacy was observed. Results The improvement of asthmatic symptoms in the experimental group was significantly better than that in the control group (P<0.05). There were no obvious adverse reactions in the children after inhalation. Conclusion Budesonide suspension for inhalation (pulmicort) inhalation combined with compound ipratropium bromide inhalation in treatment of acute asthmatic bronchitis infants is safe and effective.

    参考文献
    相似文献
    引证文献
引用本文
分享
文章指标
  • 点击次数:
  • 下载次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2017-12-18
您是第位访问者
网站版权所有:《西部医学》编辑部     蜀ICP备18038379号-4
地址:四川省成都市武侯区小天竺街75号财富国际18F-1号    邮政编码:610041
电话:028-85570072/85588403 本网站支持 IPv6    E-mail:xbyxqk@163.com
技术支持:北京勤云科技发展有限公司